Dr Mohamed Saad

Dr Mohamed Saad is a Research Scientist at the South Australian immunoGENomics Cancer Institute (SAiGENCI), University of Adelaide, Adelaide, Australia. He completed his PhD studies in 2019 at Monash University, Australia. He has authored 37 publications and been awarded numerous highly competitive scholarships, fellowships and awards, including Monash International Postgraduate Research Scholarship, Monash Publication Award, Hudson Postgraduate Travel Fellowship Award, Best Poster Prize at the Lorne Cancer conference, Milstein Travel Award from the International Cytokine and Interferon Society, and Cancer Council Victoria (CCV) Postdoctoral Research Fellowship. In 2024, he was also awarded a Cure Cancer Early Career Research grant and a Tour de Cure grant. He was selected as 1 of 6 Hudson Institute Emerging Leaders in 2021. Dr Saad has presented his work at 18 national and international conferences and symposia, and has been invited to present his work at the University of Kiel, Germany (2019) and Technical University of Munich, Germany (2024). He is an active reviewer for many scientific journals including Oncogene, Molecular Therapy - Nucleic Acids, Molecular Cancer Research, Clinical & Translational Immunology, Cancers, Cytokine, Biomolecules and Cancer Medicine. In 2023, he was invited to edit a book entitled “Patient-derived Xenografts: A Valuable Platform for Translational Cancer Research and Drug Development” to be published (by mid-2024) in the highly regarded laboratory protocol series Methods in Molecular Biology, published by Springer Nature. He also joined the editorial board of Frontiers in Oncology as a Review Editor in 2022. His research interests include elucidating the roles of the ADAM17 protease, rhomboid pseudoproteases and IL-6 cytokine signaling in dysregulated cell proliferation, inflammation and cell death, with a particular focus on lung cancer.